Eledon Pharmaceuticals, Inc. (ELDN) — Financial statements
Income statement, balance sheet, and cash flow for Eledon Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.36↓4.0% | 0.37↑0.3% | 0.37↑91.3% | 0.20 | |
| Gross Profit | 0.00↑100.0% | -0.36↑4.0% | -0.37↓0.3% | -0.37↓91.3% | -0.20 | |
| Operating Expenses | ||||||
| R&D Expenses | 66↑27.5% | 52↑71.4% | 30↑11.9% | 27↑14.1% | 24 | |
| General & Administrative Expenses | 17 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 17↓7.0% | 18↑48.2% | 12↓0.1% | 12↓4.7% | 13 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 83↑18.6% | 70↑64.7% | 43↑8.2% | 39↑7.5% | 37 | |
| Total Costs & Expenses | 83↑18.0% | 71↑64.1% | 43↑8.1% | 40↑7.9% | 37 | |
| Operating Results | ||||||
| Operating Income | -83↓18.0% | -71↓64.1% | -43↓8.1% | -40↓7.9% | -37 | |
| Depreciation & Amortization | 0.00↓100.0% | 0.36↓4.0% | 0.37↑0.3% | 0.37↑91.3% | 0.20 | |
| EBITDA | -83↓135.2% | -35↑69.5% | -116↓32.6% | -88↓138.9% | -37 | |
| EBIT | -83↓132.9% | -36↑69.3% | -117↓32.5% | -88↓138.6% | -37 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -35↓147.4% | 74↑52.6% | 48↑688471.4% | -0.01 | |
| Other Income / Expenses | 38↑8.2% | 35↑147.4% | -74↓52.6% | -48↓688471.4% | 0.01 | |
| Income Before Tax | -46↓27.5% | -36↑69.3% | -117↓32.5% | -88↓138.6% | -37 | |
| Income Tax Expense | 0.04↓91.9% | 0.43 | 0.00 | 0.00↑100.0% | -2 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -46↓26.1% | -36↑69.0% | -117↓32.5% | -88↓154.9% | -35 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -46↓26.1% | -36↑69.0% | -117↓32.5% | -88↓154.9% | -35 | |
| Bottom-Line Net Income | -46↓26.1% | -36↑69.0% | -117↓32.5% | -88↓154.9% | -35 | |
| EPS (Basic) | -0.56↑25.3% | -0.75↓46775.0% | -0.00↑100.0% | -6.13↓163.1% | -2.33 | |
| EPS (Diluted) | -0.56↑25.3% | -0.75↑54.3% | -1.64↑73.2% | -6.13↓163.1% | -2.33 | |
| Weighted Average Shares | 82↑68.6% | 49↑97.2% | 25↑72.3% | 14↓3.6% | 15 | |
| Weighted Average Diluted Shares | 82↑68.6% | 49↑97.2% | 25↑72.3% | 14↓3.6% | 15 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.